ライフサイエンスコーパス: bronchitis

1 isease including COPD (emphysema and chronic bronchitis).

2 IgG (not IgE), and positive GM (Aspergillus bronchitis).

3 ranulomatous rhinosinusitis, and aspergillus bronchitis.

4 ay diseases, including emphysema and chronic bronchitis.

5 meningitis and one in the combined group had bronchitis.

6 ogression that are characteristic of chronic bronchitis.

7 w in primary care and in patients with acute bronchitis.

8 ons seen in chronic otitis media and chronic bronchitis.

9 f chronic obstructive pulmonary disease, and bronchitis.

10 sfunction and acute rejection or lymphocytic bronchitis.

11 tract infections, including otitis media and bronchitis.

12 e respiratory diseases such as pneumonia and bronchitis.

13 no better than low-dose vitamin C for acute bronchitis.

14 ted, FEV(1)/FVC < 90% predicted) and chronic bronchitis.

15 excess of that seen in patients with chronic bronchitis.

16 (LOD = 1.21) and 22 (LOD = 1.37) for chronic bronchitis.

17 es of physician-diagnosed asthma and chronic bronchitis.

18 eas of CD3(+) CD8(+) T cell-rich lymphocytic bronchitis.

19 in patients with smoking-associated chronic bronchitis.

20 c fibrosis (CF) causes a chronic destructive bronchitis.

21 pneumonia and acute exacerbations of chronic bronchitis.

22 y airway diseases such as asthma and chronic bronchitis.

23 treatment of adults with uncomplicated acute bronchitis.

24 pathogen of humans, and causes pneumonia and bronchitis.

25 ough, mucus production, sinusitis, and acute bronchitis.

26 ns from the airways of patients with chronic bronchitis.

27 ere written for children diagnosed as having bronchitis.

28 luded a principal diagnosis of cold, URI, or bronchitis.

29 th common colds, 46% with URIs, and 75% with bronchitis.

30 help improve MCC in smoking-related chronic bronchitis.

31 gm other than when accompanied by a cold, or bronchitis.

32 atic perfusion in most patients with plastic bronchitis.

33 ecreases in subjects with history of chronic bronchitis.

34 rapy in moderate-to-severe COPD with chronic bronchitis.

35 subphenotypes such as emphysema and chronic bronchitis.

36 illosis, chronic pulmonary aspergillosis and bronchitis.

37 g diseases such as asthma, COPD, and chronic bronchitis.

38 f chronic obstructive pulmonary disease, and bronchitis.

39 ay play a role in the development of chronic bronchitis.

40 ough, eczema, and parental history of asthma/bronchitis.

41 ith improved outcomes in patients with acute bronchitis?

42 rence from cough variant asthma/eosinophilic bronchitis, 1.1 to 20.1 [p = 0.01]).

43 ng/ml) and cough variant asthma/eosinophilic bronchitis (10.2 ng/ml) than in normal subjects (2.6 ng/

44 s similar in asthma (13.4%) and eosinophilic bronchitis (12.5%).

45 (16 mL/y [95% CI, 12-20 mL/y]), mild wheezy bronchitis (14 mL/y [95% CI, 8-19 mL/y]), wheezy bronchi

46 chitis (14 mL/y [95% CI, 8-19 mL/y]), wheezy bronchitis (16 mL/y [95% CI, 11-20 mL/y]), and persisten

47 ernatant in eight patients with eosinophilic bronchitis, 17 patients with asthma matched for sputum e

48 re significantly more likely to have chronic bronchitis (19.5% versus 6.1%) and emphysema (7.9% versu

49 rge majority of cases of uncomplicated acute bronchitis.2.

50 II/IV, or protein-losing enteropathy/plastic bronchitis) 20 years after Fontan was 70% (95% CI, 63%-7

51 ts with cough variant asthma or eosinophilic bronchitis, 20 patients with nonasthmatic chronic cough,

52 diagnosed in 71.9% (pneumonia, 42.3%; acute bronchitis, 21.9%; chronic obstructive pulmonary disease

53 (URTIs) (24%), acute sinusitis (24%), acute bronchitis (23%), otitis media (5%), pharyngitis, laryng

54 itions for one or more ARI: pneumonia (537), bronchitis (2931), sinusitis (717) and non-specific ARI

55 RI, including the common cold (53.4%), acute bronchitis (31.3%), acute sinusitis (13.6%), or acute la

56 7.7%), diarrhea (4.8%), headache (4.8%), and bronchitis (4.8%).

57 t mechanism of the bothersome cough of acute bronchitis.4.

58 42); asthma: 27 +/- 40 pg/ml (n = 11); acute bronchitis: 44 +/- 112 pg/ml (n = 14); pneumonia: 55 +/-

59 age of 50 years was 64% in those with wheezy bronchitis, 47% for those with persistent asthma, and 15

60 antibiotic treatment of uncomplicated acute bronchitis.6.

61 tions of COPD were used: symptoms of chronic bronchitis (667 subjects), physician-diagnosed emphysema

62 of cough in adults with uncomplicated acute bronchitis.7.

63 for sinusitis (adjusted proportion, 86%) and bronchitis (85%) and varied little according to fever, a

64 or the highest quartile was 0.66 for chronic bronchitis (95 percent confidence interval, 0.52 to 0.85

65 In cystic fibrosis and chronic bronchitis, airways are chronically injured by exposure

66 nd 6.4-fold (1.4, 28) higher in eosinophilic bronchitis and 1.9-fold (1.3, 2.9) and 7.7-fold (1.2, 46

67 cipients with viral infection and transplant bronchitis and again observed excessive epithelial p80 e

68 of vanadium pentoxide (V(2)O(5)) results in bronchitis and airway fibrosis.

69 ficant damage to the lungs with acute, focal bronchitis and alveolitis associated with massive pulmon

70 Childhood wheezy bronchitis and asthma are associated with an increased r

71 less prokaryote Mycoplasma pneumoniae causes bronchitis and atypical pneumonia in humans.

72 Mycoplasma pneumoniae is a major cause of bronchitis and atypical pneumonia in humans.

73 of the human respiratory mucosa, leading to bronchitis and atypical pneumonia.

74 first public hospital admission for asthma, bronchitis and bronchiolitis (International Classificati

75 Daily counts of ED visits for bronchitis and bronchiolitis (n = 80,399), pneumonia (n

76 Co-occurrence of chronic bronchitis and emphysema and/or pneumonia had a stronger

77 -Antitrypsin (AAT) deficiency predisposes to bronchitis and emphysema associated with neutrophilic ai

78 r co-occurring respiratory diseases, chronic bronchitis and emphysema continue to have a positive ass

79 Chronic bronchitis and emphysema were positively associated with

80 e pulmonary disease (COPD) comprises chronic bronchitis and emphysema, and is a leading cause of morb

81 st physician-diagnosed emphysema and chronic bronchitis and low spirometry values.

82 lymphatic imaging, in patients with plastic bronchitis and percutaneous lymphatic intervention as a

83 oniae is a major cause of community-acquired bronchitis and pneumonia in humans.

84 causing otitis media in children and chronic bronchitis and pneumonia in patients with chronic obstru

85 e of otitis media in children and of chronic bronchitis and pneumonia in patients with chronic obstru

86 re frequent causes of repeated common colds, bronchitis and pneumonia, which often occur unpredictabl

87 ne to serious lung infections that result in bronchitis and pneumonia.

88 greater incidences than referents of chronic bronchitis and self- reported asthma and emphysema.

89 Secondary complications such as bronchitis and sinusitis occurred in 15% of placebo reci

90 A history of bronchitis and/or emphysema was recorded from the medica

91 variable combined those with either chronic bronchitis and/or emphysema, together considered as chro

92 onchitic symptoms (chronic cough, phlegm, or bronchitis) and of wheeze in the previous 12 months were

93 7 of 218) had pneumonia, 32% (70 of 218) had bronchitis, and 14% (31 of 218) had colonization; in-hos

94 Is, 53% with acute sinusitis, 62% with acute bronchitis, and 65% with otitis media.

95 vere airflow limitation, symptoms of chronic bronchitis, and a history of exacerbations, whose diseas

96 e tobacco smoke exposure, emphysema, chronic bronchitis, and asthma (each condition and the combined

97 r those with history of diabetes, emphysema, bronchitis, and asthma, respectively, compared with thos

98 prevalence of self-reported asthma, chronic bronchitis, and asthma-like respiratory symptoms among w

99 respiratory conditions, including pneumonia, bronchitis, and asthma.

100 vere airflow limitation, symptoms of chronic bronchitis, and at least two exacerbations in the previo

101 with public hospital admissions for asthma, bronchitis, and bronchiolitis (International Classificat

102 dysfunction on acute rejection, lymphocytic bronchitis, and bronchiolitis obliterans syndrome stage

103 spiratory illnesses (LRI) (croup, pneumonia, bronchitis, and bronchiolitis) in the first year.

104 cute bacterial infections causing sinusitis, bronchitis, and community-acquired pneumonia.

105 independent of acute rejection, lymphocytic bronchitis, and community-acquired respiratory viral inf

106 independent of acute rejection, lymphocytic bronchitis, and community-acquired respiratory viral inf

107 fe, manifests as childhood asthma and wheezy bronchitis, and continues into early adulthood.

108 g diseases including asthma, cancer, chronic bronchitis, and cystic fibrosis.

109 piratory diseases, including asthma, chronic bronchitis, and cystic fibrosis.

110 ibit abnormal MCT, including asthma, chronic bronchitis, and cystic fibrosis.

111 airway fluid (e.g., cystic fibrosis, chronic bronchitis, and exercise-induced asthma).

112 disease includes both emphysema and chronic bronchitis, and in the case of chronic bronchitis repres

113 ic upper respiratory tract infections, acute bronchitis, and influenza) from 18 months preinterventio

114 or acute sinusitis, acute pharyngitis, acute bronchitis, and nonspecific upper respiratory tract infe

115 y disease genes for asthma, COPD and chronic bronchitis, and occupational lung diseases.

116 of occupational exposures in asthma, chronic bronchitis, and respiratory symptoms in the Singapore Ch

117 Asthma, wheezy bronchitis, and wheezing were ascertained by interview a

118 h childhood asthma; 53 with childhood wheezy bronchitis; and 239 control subjects (of whom 57 develop

119 atasvir-voxilaprevir alone were diarrhea and bronchitis; and with sofosbuvir-velpatasvir-voxilaprevir

120 biomarker and therapeutic target for chronic bronchitis appear to be warranted.

121 opriate antibiotic use for adults with acute bronchitis apply to immunocompetent adults without compl

122 well as bronchiolitis obliterans and chronic bronchitis are chronic lung diseases characterized by ai

123 FEV1 below 60%, FEV1 below 80%, and chronic bronchitis are each approximately three in current or ex

124 Results for bronchitis are more positive, although intervention tria

125 onia, atypical pneumonia, bronchiolitis, and bronchitis-are responsible for much morbidity and mortal

126 ce area (emphysema) and airway inflammation (bronchitis) as the consequence of cigarette smoke (CS) e

127 bjects and compared large-airway lymphocytic bronchitis assessed by a 0-2 "E-score" and with standard

128 'Minor' sequelae (chronic bronchitis, asthma, other abnormal pulmonary function, o

129 ncidence of influenza-like illness and acute bronchitis at that time.

130 upper respiratory infection, croup, asthma, bronchitis, bronchiolitis, a wheezy lower respiratory in

131 Autopsy revealed severe necrotizing bronchitis, bronchiolitis, and interstitial pneumonitis.

132 ry-tract symptoms but, more frequently, with bronchitis, bronchiolitis, and pneumonia.

133 e respiratory tree and can cause tracheitis, bronchitis, bronchiolitis, diffuse alveolar damage with

134 ry illness in the first year of life (croup, bronchitis, bronchiolitis, or pneumonia) (RR = 2.25; 95%

135 acute perivascular rejection and lymphocytic bronchitis/bronchiolitis (LBB), and the grades were tota

136 of patients with cystic fibrosis and chronic bronchitis but not in the respective controls.

137 L-12 was also inducible during paramyxoviral bronchitis, but in this case, initial IL-12 p70 expressi

138 ammatory diseases such as asthma and chronic bronchitis, but the mechanisms and consequences of the c

139 s suggest that antibiotic treatment of acute bronchitis can be reduced by using a combination of pati

140 ults diagnosed as having uncomplicated acute bronchitis can be safely reduced using a combination of

141 proximately 10% of pneumonia cases and 5% of bronchitis cases are attributed to C. pneumoniae infecti

142 Chronic bronchitis (CB) is a common but variable phenomenon in c

143 Chronic bronchitis (CB) is characterized by persistent cough and

144 in clinically stable and acutely ill chronic bronchitis (CB) patients.

145 s obstruction and the development of chronic bronchitis (CB).

146 -years of smoking, and asthma, emphysema, or bronchitis (chronic obstructive pulmonary disease) were

147 seen in respiratory disorders (eg, asthma or bronchitis, chronic obstructive pulmonary disease (COPD)

148 nd associated diseases, e.g. asthma, chronic bronchitis, chronic obstructive pulmonary disease, and h

149 (nose, eyes, and throat irritations; cough; bronchitis; cold; wheezing; asthma attacks), medication

150 eloped necrotizing rhinitis, tracheitis, and bronchitis comparable to diacetyl-induced injury.

151 pper respiratory tract infections, and acute bronchitis, conditions that are primarily viral.

152 hildren diagnosed as having colds, URIs, and bronchitis, conditions that typically do not benefit fro

153 A history of chronic bronchitis conferred a relative risk of 1.47 (95% CI: 1.

154 E, namely airway hyperresponsiveness (AHR), bronchitis, cough reflex hypersensitivity, damage to the

155 act infection; however, for otitis media and bronchitis, declines were only observed in the populatio

156 Patient satisfaction with care for acute bronchitis depends most on physician-patient communicati

157 biotic prescriptions for uncomplicated acute bronchitis during baseline and study periods.

158 xposure, atopic diseases), symptoms (chronic bronchitis, dyspnea-modified Medical Research Council sc

159 f nonmalignant respiratory diseases (asthma, bronchitis, emphysema, hay fever, and pneumonia) in 1,55

160 redicted, in males whose parents had asthma, bronchitis, emphysema, or hay fever and with increased p

161 redicted, in males whose parents had asthma, bronchitis, emphysema, or hay fever.

162 the role of previous lung diseases (chronic bronchitis, emphysema, pneumonia, and tuberculosis) in t

163 ate lung cancer risk associated with chronic bronchitis, emphysema, tuberculosis, pneumonia, and asth

164 al class, physical activity index, prevalent bronchitis/emphysema, and prevalent asthma.

165 ns even in asthma patients with neutrophilic bronchitis, EPX-based ELISA levels are not increased in

166 In chronic bronchitis, few cells were GCRbeta-positive and their nu

167 pper respiratory tract infections, and acute bronchitis (for which routine antibiotic treatment is no

168 Bacterial bronchitis (four patients) and obstructive granulomas (t

169 g chronic cough include asthma, eosinophilic bronchitis, gastro-oesophageal reflux disease, postnasal

170 otitis media, sinusitis, and exacerbation of bronchitis, has acquired widespread ability to produce b

171 yperplasia, histological features of chronic bronchitis, have been linked to epidermal growth factor

172 =1.23; 95% CI: 0.97, 1.55) and bronchiolitis/bronchitis (HR=1.13; 95% CI: 0.99, 1.30).

173 e cells induced a lymphocytic vasculitis and bronchitis, ICAM-1 mutant allogeneic BAL cells only indu

174 edia in children and exacerbation of chronic bronchitis in adults.

175 inosis, chest tightness at work, and chronic bronchitis in cotton workers.

176 d increased odds of reduced FEV1 and chronic bronchitis in current or ex-smoking first-degree relativ

177 s 1.64 at chromosome 19, whereas for chronic bronchitis in smokers only, the maximum LOD was 2.08 at

178 The bronchitis index scores were significantly higher in mar

179 nd airway secretions using a modified visual bronchitis index.

180 Eosinophilic bronchitis is a common cause of chronic cough, which lik

181 Pulmonary emphysema, together with chronic bronchitis is a part of chronic obstructive pulmonary di

182 Plastic bronchitis is a potentially fatal disorder occurring in

183 liary clearance associated with mild chronic bronchitis is acutely improved with minimal doses of aer

184 Acute bronchitis is an acute cough illness in otherwise health

185 In conclusion, eosinophilic bronchitis is associated with active airway inflammation

186 onstrated, it is unclear if childhood wheezy bronchitis is associated with COPD.

187 antibiotic treatment of uncomplicated acute bronchitis is not recommended, regardless of duration of

188 value of azithromycin for treatment of acute bronchitis is unknown, even though this drug is commonly

189 ng allografts that contribute to lymphocytic bronchitis (LB) and bronchiolitis obliterans (BO).

190 t COPD probands for reduced FEV1 and chronic bronchitis, limited to current or ex-smokers, suggests g

191 ; 95% CI: 1.47-3.65), daily intake of asthma/bronchitis medication (OR = 2.26; 95% CI: 1.42-3.58), fi

192 Daily intake of asthma/bronchitis medication and incidence of asthma, allergic

193 rgic rhinitis, atopic dermatitis, and asthma/bronchitis medication.

194 of UTP in chronic smokers with mild chronic bronchitis (n = 15) by measuring the clearance of (99m)T

195 n = 189,816), and for 0- to 18-year-olds for bronchitis (n = 76,243), chronic sinusitis (n = 15,745),

196 n 137 patients with COPD and 26 with chronic bronchitis (normal spirometry).

197 air pollutants are important determinants of bronchitis occurrence.

198 terval, 3.73-10.94), as was childhood wheezy bronchitis (odd ratio 1.81; 95% confidence interval, 1.1

199 We evaluated lymphocytic bronchitis on endobronchial biopsies as a risk factor fo

200 g toxic effects were hospital admissions for bronchitis (one) and pleural effusion (one), grade 3 inc

201 ve association with lung cancer than chronic bronchitis "only." Asthma had an inverse association wit

202 ins were more likely to cause pneumonia than bronchitis or colonization, respectively.

203 uded a doctor's diagnosis of asthma, chronic bronchitis or COPD, and a history of wheezing or use of

204 14% vs. 10%), while similar rates of chronic bronchitis or emphysema (1% vs. 1%) and asthma (1% vs. 1

205 ng cough or shortness of breath), 2) chronic bronchitis or emphysema, and 3) asthma.

206 s (within 30 days of the incident visit) for bronchitis or pneumonia did not change significantly for

207 nfidence interval (CI): 1.08, 1.30), chronic bronchitis (OR = 1.26, 95% CI: 1.01, 1.57), and adult-on

208 confidence interval (CI) 1.10-3.43), chronic bronchitis (OR = 1.73, 95% CI 1.10-2.72), and the combin

209 I, 1.0-3.6) but not with asthma, hoarseness, bronchitis, or a history of pneumonia.

210 Bronchitis, or airway inflammation, may be predominantly

211 the combined endpoint of emphysema, chronic bronchitis, or asthma (OR = 1.82, 95% CI 1.26-2.63).

212 bstruction (CAO), defined as asthma, chronic bronchitis, or emphysema.

213 Patients were grouped by colonization, bronchitis, or pneumonia and were compared for different

214 e pulmonary diseases (COPDs) such as asthma, bronchitis, or pneumonia.

215 rence in efficacy by sex, history of chronic bronchitis, oxygen use, or concomitant COPD therapy.

216 ponse by sex (P = 0.75), presence of chronic bronchitis (P = 0.19), concomitant inhaled therapy (P =

217 alue) and with an increased risk of allergic bronchitis (p = 1.77*10(-4) and p = 7.94*10(-4), respect

218 ay quantitate a key component of the chronic bronchitis pathophysiologic cascade that produces sputum

219 ction, in children with protracted bacterial bronchitis (PBB) and mild bronchiectasis (BE).

220 hogen that frequently causes ear infections, bronchitis, pneumonia, and exacerbations in patients wit

221 waterborne pathogen responsible for causing bronchitis, pneumonia, and gastrointestinal infections,

222 Chronic bronchitis, pneumonia, emphysema, and asthma were associ

223 Data from chronic-bronchitis questionnaires and data on total mucin concen

224 level and increased asthma and bronchiolitis/bronchitis rates in childhood were consistent with a pre

225 ronic bronchitis, and in the case of chronic bronchitis represents an inflammatory response of the ai

226 owing Medical Subject Headings terms: "acute bronchitis," "respiratory tract infection," "pharyngitis

227 Mouse paramyxoviral bronchitis resulted in airway epithelial cell infection

228 COPD), which comprises emphysema and chronic bronchitis resulting from prolonged exposure to cigarett

229 e fluid secretions in infectious or allergic bronchitis/rhinitis.

230 (RR, 1.15; 95% CI, 1.00-1.32; P = .05), and bronchitis (RR, 1.18; 95% CI, 1.01-1.37; P = .04) at any

231 tions: RR, 1.15; 95% CI, 0.97-1.35; P = .11; bronchitis: RR, 1.20; 95% CI, 1.01-1.43; P = .04).

232 presumptive diagnosis of uncomplicated acute bronchitis should focus on ruling out serious illness, p

233 ng influenza outbreaks, including pneumonia, bronchitis, sinusitis, and otitis media.

234 ified Medical Research Council >/=2, chronic bronchitis, St. George's Respiratory Questionnaire >25,

235 atic compared with normal control or chronic bronchitis subjects.

236 Information on current bronchitis symptoms and asthma, home environment, and de

237 associations of e-cigarette use with chronic bronchitis symptoms and wheeze in an adolescent populati

238 king, bronchodilator responsiveness, chronic bronchitis symptoms, and index case status.

239 tructive pulmonary disease (COPD)-associated bronchitis than in those from throats of healthy individ

240 on and susceptibility to recurrent infective bronchitis that may, in turn, contribute to further ster

241 In eosinophilic bronchitis the mean concentration of sputum PGD(2) (0.79

242 kage of mild airflow obstruction and chronic bronchitis to several genomic regions; for mild airflow

243 sistent with acute rejection and lymphocytic bronchitis, to subepithelial and intraluminal fibrotic l

244 reatment-related sinusitis, pneumonia, viral bronchitis, tooth infection, stomatitis, and leukopenia

245 neric term encompasses emphysema and chronic bronchitis, two common conditions, each having distinct

246 ronic obstructive pulmonary disease, chronic bronchitis, two or more exacerbations and/or hospitaliza

247 A sample enriched for asthma and chronic bronchitis underwent a further questionnaire, pre- and p

248 initiate antibiotic therapy in patients with bronchitis unless pneumonia is suspected.

249 er risk of atopic dermatitis and obstructive bronchitis until 3 years.

250 er risk of atopic dermatitis and obstructive bronchitis until age 3 years.

251 eral gammacoronaviruses including infectious bronchitis virus (IBV) contain a putative open reading f

252 tein from the group 3 coronavirus infectious bronchitis virus (IBV) contains a canonical dilysine end

253 he genomic RNA of the coronavirus infectious bronchitis virus (IBV) contains a classic hairpin-type R

254 t signal of the avian coronavirus infectious bronchitis virus (IBV) contains two cis-acting signals e

255 we show that the Gammacoronavirus infectious bronchitis virus (IBV) does induce host shutoff, and we

256 r investigate the function of the infectious bronchitis virus (IBV) E protein, we developed a recombi

257 The E protein from the avian infectious bronchitis virus (IBV) has dramatic effects on the secre

258 her viruses, the gammacoronavirus infectious bronchitis virus (IBV) has evolved under evolutionary pr

259 the E protein of the coronavirus infectious bronchitis virus (IBV) is localized to the Golgi complex

260 n the present study, we show that infectious bronchitis virus (IBV) is resistant to IFN treatment and

261 The pseudoknot found in infectious bronchitis virus (IBV) is typical of those that possess

262 in the intracellular targeting of infectious bronchitis virus (IBV) membrane proteins.

263 The potential interactome of the infectious bronchitis virus (IBV) N protein was mapped using stable

264 Infectious bronchitis virus (IBV) ORF 3a is one such gene.

265 cement using the homologous avian infectious bronchitis virus (IBV) structure.

266 gence of a nephropathogenic avian infectious bronchitis virus (IBV) with a novel genotype in India.

267 ant domains of the N protein from infectious bronchitis virus (IBV), a prototype coronavirus.

268 While infectious bronchitis virus (IBV), a respiratory pathogen of chicke

269 otein from the avian coronavirus, infectious bronchitis virus (IBV), contains information for localiz

270 he prototypical Gammacoronavirus, infectious bronchitis virus (IBV), induces a delayed activation of

271 strain of avian Gammacoronavirus infectious bronchitis virus (IBV), induces regions of ER that are z

272 mmacoronavirus, including chicken infectious bronchitis virus (IBV), require specific alpha2,3-linked

273 the frameshifting pseudoknot from infectious bronchitis virus (IBV), three constituent hairpins, and

274 y employing the avian coronavirus infectious bronchitis virus (IBV).

275 oplasmic tail of the S protein of infectious bronchitis virus (IBV).

276 th the important poultry pathogen infectious bronchitis virus (IBV).

277 ble to inhibit the early phase of infectious bronchitis virus and Dengue infection, in addition to th

278 aracterization of CoV N NTDs from infectious bronchitis virus and from severe acute respiratory syndr

279 tail for two other coronaviruses, infectious bronchitis virus and the severe acute respiratory syndro

280 erimental data for adenovirus and infectious bronchitis virus infections as examples, we demonstrate

281 domain targeting signal from the infectious bronchitis virus M protein and the lumenal and cytoplasm

282 acid identity similar to that of infectious bronchitis virus N protein and shares a higher level of

283 ellular localization of the avian infectious bronchitis virus N protein both in the absence and in th

284 9N2, Newcastle disease virus, and infectious bronchitis virus were found.

285 Chronic bronchitis was associated with increased frequencies of

286 increased with childhood asthma, and wheezy bronchitis was associated with reduced FEV1 that was evi

287 Prescribing antibiotics for acute bronchitis was associated with reduced overall and night

288 Endobronchial lymphocytic bronchitis was more prevalent in subjects in BOS stage 0

289 probands for airflow obstruction and chronic bronchitis was performed to determine whether significan

290 Acute bronchitis was the predominant lower respiratory infecti

291 exposure to pets, doctor's diagnosed wheezy bronchitis (WB), and compositional changes in the gut mi

292 the prevalence odds ratios (ORs) for chronic bronchitis were 0.98, 0.88, and 0.69 for the second, thi

293 c prescription rates for uncomplicated acute bronchitis were similar at all 4 sites during the baseli

294 The occurrence of chest infections, bronchitis, wheeze, and eczema in children was assessed

295 g acute otitis media, sinusitis, and chronic bronchitis, which are preceded by asymptomatic H. influe

296 ic obstructive pulmonary disease and chronic bronchitis who are at risk of frequent and severe exacer

297 rrected congenital heart disease and plastic bronchitis who presented for lymphatic imaging and inter

298 s active airway inflammation in eosinophilic bronchitis, with reduced release of important effector m

299 Adults diagnosed with acute bronchitis, without evidence of underlying lung disease,

300 cin concentration and a diagnosis of chronic bronchitis yielded areas under the curve of 0.72 (95% co